myelin oligodendrocyte glycoprotein antibody-associated disease
Conditions
Interventions
Patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD):None
Patients with monophasic myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD):None
Sponsors
The Third Affiliated Hospital Sun Yat-sen University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with a clinical diagnosis of MOGAD who meet the 2023 International MOGAD Panel diagnostic criteria. 2. Informed consent is obtained from prospectively enrolled cases.
Exclusion criteria
Exclusion criteria: 1. Definitively diagnosed with other inflammatory demyelinating diseases of the central nervous system (multiple sclerosis, neuromyelitis optica spectrum disorders). 2. Definitively diagnosed with non-MOG-IgG-related autoimmune encephalitis; 3. Central nervous system infections, vascular diseases, tumors, genetic metabolic/mitochondrial diseases, and other non-inflammatory demyelinating disorders; 4. Definitively diagnosed as demyelinating disorders caused by drugs or toxins; 5. Patients refuse to provide informed consent, or there are circumstances that the investigator considers unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disability level at each follow-up visit and at the time of disease relapse;Annual relapse rate in MOGAD patients; | — |
Countries
China
Contacts
Public ContactQiu Wei
The Third Affiliated Hospital Sun Yat-sen University
Outcome results
None listed